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Objectives. This study was performed to evaluate the frequency 
dependency of ventricular repolarization and the effect of epi- 
nephrine in patients with congenital long QT syndrome (LQTS). 
Background. The efficacy of pacemakers in addition to anti- 
adrenergic therapy in the treatment of congenital LQTS has been 
reported. 
Methods. Monophasic action potentials were recorded from 
right and left ventricular endocardium during atrial pacing at 
heart rates from 70 to 140 beats/min at baseline and from 100 to 
140 beats/min during epinephrine infusion (0.1 ~g/kg body weight 
per min) in 11 patients with congenital LQTS and 10 control 
patients. The response of monophasic action potential duration at 
90% repolarization (MAPD90) and the dispersion of MAPD90 
were examined. 
Results. At baseline, both the MAPD90 and the dispersion of 
MAPD90 were significantly (p < 0.001) longer in the congenital 
LQTS group than the control group. The differences in these 
variables between the two groups significantly decreased 
(MAPD90: from 105 to 31 ms; dispersion of MAPD90: from 55 to 
13 ms, p < 0.001) as heart rate was increased. Epinephrine 
prolonged the MAPD90 and increased the dispersion of MAPD90 
significantly (p < 0.001) at all paced heart rates in the congenital 
LQTS group without frequency dependency but did not change in 
the control group. Thus, epinephrine increased the differences in 
these variables between the two groups. 
Conclusions. The repolarization abnormalities in congenital 
LQTS were attenuated by increasing the heart rate, which sup- 
ported the efficacy of pacemaker therapy. However, during sym- 
pathetic stimulation, the effects of increased heart rate on these 
repolarization abnormalities were limited. 
(JAm CoU Cardiol 1996;28:1269-77) 
Congenital long QT syndrome (LQTS) is a hereditary disorder 
characterized by prolongation of the QT interval and by 
syncopal episodes and sudden death due to ventricular ar- 
rhythmias (1-3). The present treatment ofchoice is antiadren- 
ergic therapy (e.g., beta-adrenergic blocking agents, left cervi- 
cothoracic sympathetic ganglionectomy) because an increase 
in sympathetic stimulation, such as stress or fright, can precip- 
itate ventricular tachyarrhythmias in the setting of QT prolon- 
gation (4,5). In contrast, he efficacy of permanent pacemakers 
has also been reported (6,7) in the treatment of patients with 
congenital LQTS who are resistant to beta-blockers and left 
cervicothoracic sympathetic ganglionectomy. 
It has been reported that increases in heart rate due to 
exercise (8,9) and isoproterenol infusion (9,10) produce a 
paradoxic prolongation of the QT interval and may precipitate 
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ventricular arrhythmias in patients with congenital LQTS. 
However, exercise or isoproterenol infusion influences both 
heart rate and adrenergic activities. The influence of heart rate 
on ventricular repolarization without adrenergic a tivities (e.g., 
pacing) has not been thoroughly evaluated in congenital 
LQTS. 
The purpose of the present study was to evaluate the 
influence of heart rate on ventricular repolarization i  patients 
with congenital LQTS by using monophasic action potentials 
and atrial pacing, which has little effect on adrenergic activities, 
and to assess the effects of epinephrine on these variables. 
Methods  
Subjects. This study used a patient-control design. Inclu- 
sion criteria for patients with congenital LOTS followed the 
1993 LOTS diagnostic riteria of Schwartz et al. (11). Eleven 
patients who met these criteria entered the present study (nine 
female, two male; 3 to 63 years old, mean [_+SD] age 31 + 19) 
(Table 1). Seven patients had familial congenital LQTS 
(Romano-Ward syndrome), and four had idiopathic ongenital 
LQTS. All 11 patients had a history of stress-induced syncope. 
Polymorphic ventricular tachycardia characteristic of torsade 
de pointes was documented in seven patients. The mean 
corrected QT (QTc) interval in the LQTS group was 540 -+ 
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Abbreviations and Acronyms 
ANOVA = analysis of variance 
ECG = electrocardiogram, electrocardiographic 
LQTS = long QT syndrome 
MAPD90 = monophasic action potential duration at 90% 
repolarization 
QTc = corrected QT interval 
91 ms 1/2 (range 450 to 740). All 11 patients had a score of four 
or more points according to the diagnostic riteria of Schwartz 
et al. (11), indicating a high probability of congenital LQTS. 
The criteria for the control group were 1) QTc interval 
<440 msl/2; and 2) no history of syncope or ventricular 
arrhythmias. There were 10 control patients, of whom 4 had 
sick sinus syndrome, and 6 had concealed Wolff-Parkinson- 
White syndrome (4 women, 6 men; 45 to 74 years old, mean 
age 59 _+ 8). The mean QTc interval in the control group was 
405 + 18 ms 1/2 (range 370 to 420). 
Electrophysiologic studies. The protocol was reviewed and 
approved by our Ethical Review Committee, and written 
informed consent was obtained from all participants before the 
study. Because two patients in the LQTS group were minors, 
we obtained informed consent from their parents. Electro- 
physiologic studies were performed in the nonsedated, post- 
absorbed state in all but two patients in the LQTS group 
(Patients 8 and 10) who received sodium pentobarbital 
(3 mg/kg body weight) and diazepam (0.3 mg/kg) as sedation. 
All antiarrhythmic medications had been discontinued for at 
least 5 drug half-lives. 
Two or three 6F or 7F monophasic action potential cathe- 
ters (monophasic action potential-pacing combination cathe- 
ter, EP Technologies Inc.) were introduced through a femoral 
vein and advanced into the right ventricle under fluoroscopic 
guidance to record the right ventricular monophasic action 
potentials. Another 6F or 7F catheter was introduced through 
a femoral artery and advanced into the left ventricle to record 
the left ventricular monophasic action potential. A standard 6F 
bipolar electrode catheter with 10-ram interelectrode spacing 
(USCI Inc.) was positioned in the right atrial appendage for 
atrial pacing. 
Monophasic action potential recordings. Monophasic ac- 
tion potentials were recorded simultaneously from two or 
three sites at the right or left ventricular endocardium, or both, 
in each patient by the contact electrode technique, as described 
previously (9,12-16). A total of 33 sites were recorded in 11 
patients in the LQTS group and 26 in 10 control patients. In 
the right ventricle, monophasic action potential recordings 
were obtained from two sites in all patients with congenital 
long QT syndrome and all control patients. In the left ventricle, 
those were obtained in all patients in the LQTS group syn- 
drome but in only six control patients. Readings of monophasic 
action potentials, six surface electrocardiographic leads and 
arterial pressure through a radial artery were displayed simul- 
taneously on a strip-chart recorder (Siemens-Elema, 16- 
Table 1. Clinical Characteristics of 11 Patients With Congenital Long QT Syndrome and 10 Control Patients 
Syncope Yorsade de 
Pt No. Age (yr)/Gender Diagnosis With Stress Pointes SCL (ms) QT (ms) QYc (ms) 
LQTS group 
1 30/F Romano-Ward 
2 29/F Idiopathic 
3 27,;F Romano-Ward 
4 33/1= Romano-Ward 
5 45/F Romano-Ward 
6 23/F Romano-Ward 
7 18/1= Idiopathic 
8 3/M Romano-Ward 
9 58/M Idiopathic 
10 9/3 c Romano-Ward 
11 637F Idiopathic 
Control group 
1 61/M SSS 
2 45/F SSS 
3 55/M Con WPW 
4 67/M SSS 
5 56fF SSS 
6 59/M Con WPW 
7 52/F Con WPW 
8 74/M Con WFW 
9 57/M Con WPW 
10 62/F Con WPW 
+ + 710 400 480 
+ + 600 390 500 
+ + 780 490 550 
+ - 780 400 450 
+ - 890 450 480 
+ + 1,180 710 650 
+ - 940 560 580 
+ + 740 640 740 
* - 960 450 460 
+ + 850 440 480 
+ + 960 480 490 
1,360 430 370 
820 380 420 
1,020 420 420 
970 410 420 
1,280 430 380 
850 370 400 
98O 410 410 
930 385 400 
1,000 410 410 
860 390 420 
Con WPW = concealed Wolff-Parkinson-White syndrome; F = female; LQTS = congenital long QT syndrome; M = male; Pt = patient; QTc = corrected QT 
interval; SCL = sinus cycle length; SSS = sick sinus syndrome. 
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channel Mingograf) at a paper speed of 100 mm/s. Signals of 
monophasic action potentials were amplified and filtered at a 
frequency of 0.05 to 500 Hz, and those of ventricular electro- 
grams were amplified and filtered at a frequency of 50 to 
500 Hz. Monophasic action potentials were obtained after 
placement of the catheter electrode in a position providing 
continuous recordings of stable amplitude, smooth configura- 
tion and isopotential diastolic baselines (phase 4) from a single 
endocardial site during both sinus rhythm and constant atrial 
pacing. Once the contact catheter was stabilized, monophasic 
action potentials could be recorded continuously from the 
same endocardial site for long periods without additional 
manipulation of the catheter. 
The duration of monophasic action potential was deter- 
mined at 90% repolarization (MAPD90), which included early 
afterdepolarization-like activity if present. The dispersion of 
MAPD90 was defined as the difference between the longest 
MAPD90 and the shortest MAPD90 in each patient. The QT 
interval was measured in all 12 leads, and the longest QT 
interval was used for analysis. The QT(U) interval was defined 
as the time between QRS onset and the point at which the line 
of maximal downslope of the T wave [or the late component of
the T(U) complex, if present] crossed the baseline before the 
isoelectric UP interval. The QTc interval was calculated ac- 
cording to Bazett's formula (QTc = QT/x/RR). QRS duration 
was determined by measuring the QRS duration in lead II 
from beginning to end. 
Protocol. The following protocol was used to investigate 
the response of MAPDg0, dispersion of MAPD90, QT interval 
and QRS duration for various heart rates at steady state for 
comparison between the LQTS and control groups. Constant 
right atrial pacing was performed with 2-ms rectangular stimuli 
at twice diastolic threshold elivered from a programmable 
stimulator (Nihon Kohden Inc., model SEL-3120) in both 
groups. Right atrial pacing at 70, 80, 100, 120 and 140 
beats/min was performed. Monophasic action potential record- 
ings were obtained uring constant atrial pacing for at least 
3 rain at each heart rate until monophasic action potential 
duration had reached a new steady state (12,13). Each pacing 
run was followed by a recovery period of at least 3 rain. The 
mean MAPD90 and QT intervals of at least 4 consecutive 
beats during constant atrial pacing were used for analysis. 
Epinephrine infusion, After baseline study, epinephrine 
was infused at a constant rate of 0.1 txg/kg body weight per rain 
in both groups. After a steady state was achieved, the previ- 
ously described protocol was repeated. Because sinus heart 
rate increased >90 beats/min after epinephrine infusion in 
almost all patients, right atrial pacing was performed only at 
100, 120, and 140 beats/rain during epinephrine infusion. 
Data analysis. Data were evaluated as differences in 
MAPD90, dispersion of MAPDg0, QT interval, and QRS 
duration between the groups (LQTS group vs. control group) 
or within the groups (control state vs. epinephrine) at each 
heart rate. Results are expressed as mean value + SD. The 
differences in each measurement (MAPD90, dispersion of 
MAPD90, QT interval and QRS duration) between the groups 
in relation to heart rate during the control state and epineph- 
rine infusion were tested using multiple regression analysis 
with dummy variables. We used Y = c + b~'D + b2"HR + 
b3.D.HR as regression model, where Y = the measured 
variable (MAPD90, dispersion of MAPD90, QT interval and 
QRS duration); c, b 1, b 2 and b 3 = estimated regression 
coefficients; HR = heart rate; and D = a dummy variable for 
the group (control group = 0, LQTS group = 1). The changes 
in each measurement before and after epinephrine infusion 
within the groups as a function of heart rate were determined 
using repeated measures analysis of variance (ANOVA) with 
the Greenhouse-Geisser correction for within-subject orrela- 
tions (17). Differences within groups (control state vs. epineph- 
rine) or between groups (LQTS group vs. control group) at 
each heart rate were also analyzed by the Student t test (paired 
or unpaired). Values of p < 0.05 were considered statistically 
significant. 
Resu l ts  
Clinical characteristics. Clinical characteristics of the 11 
LQTS group patients and the 10 control group patients are 
shown in Table 1. All 11 LQTS group patients had a prolonged 
QTc interval. The mean QTc interval during sinus rhythm 
before epinephrine infusion was 540 _+ 91 ms v2 (range 450 to 
740 ms 1/2) in the LQTS group and 405 z 18 ms 1/2 (range 370 
to 420 ms v2) in the control group. Epinephrine significantly 
shortened the sinus cycle length in both groups (LQTS group: 
from 914 _+ 102 to 620 _+ 50 ms, p < 0.0005; control group: 
from 1,013 _+ 180 to 740 _+ 120 ms, p < 0.005). 
Response of MAPD90 to heart rate (Table 2). During the 
control state, at paced heart rates of 70, 80, 100, 120, and 140 
beats/rain, the mean MAPD90 was, respectively, 395 _+ 60, 
345 _+ 52, 310 _+ 42, 275 _+ 28 and 239 _+ 16 ms in the LQTS 
group (n = 33 sites: 22 in the right ventricle, 11 in the left 
ventricle) (Fig. 1, upper panel) and 290 _+ 26, 272 + 20, 248 _+ 
19, 232 z 17 and 208 + 10 msec in the control group (n = 26 
sites: 20 in the right ventricle, 6 in the left ventricle) (Fig. 2, 
upper panel) and was significantly (p < 0.001) longer in the 
LQTS group than in the control group at all heart rates tested. 
Although the mean MAPD90 decreased with increasing heart 
rate in both groups, the differences in mean MAPD90 between 
the LQTS and control groups were 105, 73, 62, 43 and 31 ms, 
respectively, ateach paced heart rate, indicating attenuation f 
difference of the MAPD90 between the two groups at faster 
heart rates. Moreover, the MAPD90, which was examined over 
the range of paced heart rates, was significantly longer at 
slower than at faster paced heart rates (p < 0.001) in the LQTS 
group. 
During epinephrine infusion, the MAPD90 was prolonged 
significantly (p < 0.001 by ANOVA) to 339 _+ 59, 310 + 57 and 
278 - 52 ms, respectively, in the LQTS group at all paced heart 
rates of 100, 120, and 140 beats/rain tested (Fig. 1, lower 
panel). The degrees of prolongation of mean MAPD90 com- 
pared with the control state were 29 ms (9%), 35 ms (13%), 
and 39 ms (16%), respectively, atpaced heart rates of 100, 120 
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Table 2. MAPD90 and Dispersion of MAPD90 in Relation to Paced Heart Rate and Effect of Epinephrine on MAPD90 and Dispersion of 
MAPD90 in 11 Patients With Congenital Long QT Syndrome and 10 Control Patients 
Paced Heart Rate 
70 beats/rain 80 beats/min 100 beats/rain 120 beats/min 140 beats/min 
Dispersion Dispersion Dispersion Dispersion Dispersion 
of of of of of 
No. of Sites MAPD90 MAPD90 MAPD90 MAPD90 MAPD90 MAPD90 MAPD90 MAPD90 MAPD90 MAPD90 
Group Sampled (ms) (ms) (ms) (ms) (ms) (ms) (ms) (ms) (ms) (ms) 
Control state 
LQTS group 33 
Control group 26 
A 
Epinephrine 
LOTS group 33 
Control group 26 
A 
395 ± 60* 78 ± 17" 345 ± 52* 54 ± 23* 310 _+ 42* 38 ± 17' 275 - 28* 27 -+ 14 239 ± 16' 27 ± 10 
290 ± 26 23 ± 10 272 ± 20 22 ± 11 248 + 19 16 _+ 9 232 : 17 18 + 8 208 _+ 10 14 + 7 
105 55 73 32 62 22 43 9 31 13 
339 2 59t:~ 62 • 33§11 310 ± 57[:[: 52 ± 36§11 278 ± 52t~c 35 ~+ 15§[I 
260 ± 24 19 ± 11 236_+ 15 16 ± 10 213 ± 13 18 ± 4 
79 43 74 36 65 17 
*p < 0.001 versus Control group (Control state), i'p < 0.001 versus congenital long QT syndrome (LOTS) group (Control state). :~p < 0.001 versus Control group 
(Epinephrine). §p< 0.05 versus LQTS group (Control state), lip < 0.05 versus Control group (Epinephrine). Data are expressed asmean value ± SD or difference 
(A) between mean value in LQTS group and that in Control group at each heart rate. MAPD90 = monophasic a tion potential duration at 90% repolarization. 
and 140 beats/min. Epinephrine- induced changes in the 
MAPD90 in the LOTS group were not frequency dependent. 
In the control group, there was a tendency to prolongation of 
the MAPD90 to 260 _+ 24, 236 ± 15 and 213 _+ 13 ms at all 
heart rates tested, but there were no significant differences 
(Fig. 2, lower panel). Therefore, the differences in the mean 
MAPD90 between the two groups increased to 79, 74 and 
65 ms at the respective paced heart rates of 100, 120 and 140 
beats/min during epinephrine infusion. When the MAPD90 
was examined over the range of paced heart rates during 
epinephrine infusion, there was no significant frequency- 
dependent relation between the two groups, indicating that 
increasing the heart rate by atrial pacing did not shorten the 
MAPD90 significantly during epinephrine infusion (Fig. 3A). 
Response of dispersion of MAPD90 to heart rate (Table 2). 
The dispersion of MAPD90 was calculated from two sites in 
the right ventricular and one site in the left ventricular 
endocardium in all patients with LQTS and six control pa- 
tients. In four control patients, dispersion of MAPD90 was 
calculated from only two sites in the right ventricular endocar- 
dium. 
During the control state, at paced heart rates of 70, 80, 100, 
120 and 140 beats/rain, the mean dispersion of MAPD90 was, 
respectively, 78 ± 17, 54 _ 23, 38 ± 17, 27 _ 14 and 27 ± 
LQTS patient 
Control state 
70/min 
V5 
QT 
RV f ree wa l l  
MAPDgo 
Epinephrine 
V5 
QT 
RV free wall 
MAPDgo 
80/rain lO0/min 120/rain 140/min 
470 ms 470 ms 410 ms 390 ms 350 ms 
310 ms 300 ms 280 ms 250 ms 225 ms 
lO0/min 120/min 140/min 
i' ,~I ~-+-H 
460 ms 415 ms 365 ms 
, . . . . . .  
330 ms 290 ms 255 ms 
Figure 1. Recordings of the monophasic 
action potential at each paced heart rate 
from 70 to 140 beats/min before epi- 
nephrine infusion (Control state, upper 
panel) and from 100 to 140 beats/min 
during epinephrine infusion (Epineph- 
rine, lower panel) in a patient with con- 
genital LQTS (Patient 5). Simultaneous 
recordings of surface ECG lead V 5 
monophasic action potential from the 
right ventricular (RV) free wall. The 
measurements below each recording are 
the QT interval and the MAPD90 at 
each heart rate. As heart rate was in- 
creased by constant atrial pacing, both 
the QT interval and the MAPD90 were 
shortened. Epinephrine prolonged both 
QT interval and MAPD90 at all paced 
heart rates of 100, 120 and 140 beats/ 
min. 
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Figure 2. Recordings of monophasic action 
potential at each paced heart rate from 70 to 
140 beats/min before epinephrine infusion 
(Control state, upper panel) and from 100 to 
140 beats/rain during epinephrine infusion 
(Epinephrine, lower panel) in a control pa- 
tient (Patient 8). Simultaneous recordings of 
surface ECG lead V 3 monophasic action po- 
tential from the right ventricular (RV) apex. 
The measurements below each recording are 
the QT interval and the MAPD90 at each 
heart rate. As heart rate was increased by 
constant atrial pacing, both the QT interval 
and the MAPD90 were shortened. Epineph- 
rine did not change markedly both the QT 
interval or the MAPD90 at any heart rate. 
V3 ~r] 
QT 
RV apex I 
r 
MAPDgo 
Epinephrine 
Control patient 
Control state 
70/min 80/min 100/min 120/min 140/min 
I I /' i . /I 
/ / ,i ~1 I 
350 ms 340 ms 310 ms 300 ms 280 ms 
'\ 
,\ 
255 ms 250 ms 240 ms 215 ms 205 ms 
100/min 120/min 140/min 
It Sp I 
ff kl 
QT 310 ms 290 ms 270 ms 
RV apex / 
MAPDgo 240 ms 220 ms 210 ms 
10 ms in the LQTS group (n = 11) and 23 __ 10, 22 _+ 11, 16 _+ 
9, 18 _+ 8 and 14 _+ 7 ms in the control group (n = 10) and was 
significantly (p < 0.001) greater in the LQTS group than in the 
control group at paced heart rates of 70, 80 and 100 beats/min. 
The mean dispersion of MAPD90 decreased with increasing 
heart rate in the LQTS group, whereas it was almost constant 
in the control group. Therefore, the differences in mean 
dispersion of MAPD90 between the two groups were 55, 32, 
22, 9 and 13 ms at each paced heart rate, indicating attenuation 
of difference in the dispersion of MAPD90 between the two 
groups at faster heart rates. Moreover, the dispersion of 
MAPD90, which was examined over the range of paced heart 
rates, was significantly greater at slower than at faster paced 
heart rates in the LQTS group (p < 0.001). 
During epinephrine infusion, the dispersion of MAPD90 
increased significantly (p < 0.05 by ANOVA) to 62 _ 33, 52 + 
36 and 35 _ 15 ms at paced heart rates of 100, 120 and 140 
beats/min, respectively, in the LQTS group. The degree of 
increase in mean dispersion of MAPD90 compared with that in 
the control state was 24 ms (63%), 25 ms (93%) and 8 ms 
MAPDgo 
(msec) 
450- 
400- 
350" 
Figure 3. Changes in MAPD90 (A) and dis- 
persion of MAPD90 (B) in relation to paced 
heart rate and effect of epinephrine infusion 300- 
(0.1 ;xg/kg per min) on MAPD90 and dispersion 
of MAPDg0 in 11 patients with congenital zso- 
LQTS and 10 control patients. 
200- 
A Dispersion of 
MAPDg0 (msec) 
* P< 0.001 vs. • 100- 
t P<0.001 vs. • 
~ ~ !  I P<0,001 vs. 
80- 
T 
20- 
,0 ~0 120 140 0 ~ 100 70 80 
Heart Rate (/rain) 
• LQTS group (Control state) 
O LQTS group (Epinephrine) 
ak Control group (Control state) 
- - ~-  - Control group (Epinephrine) 
B 
P< 0.001 vs. • 
t P< 0.05 vs. • 
~ ,  ] $ P<0.05 vs. A 
t l  
""- t1 
** " ",It1 
0o ' ' 1 120 140 
Heart Rate (/rain) 
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QT interval 
(ms) 
550- 
500 
450" 
400. 
350- 
300- 
250 
A 
* P<0.001 vs .•  
~" P< 0.001 vs. • 
~: P<0.001 vs. G I. 
70 80 100 120 140 
Heart Rate (/rain) 
QRS duration 
(ms) 
160 
140 
120 
I00 
L! 
70 80 
~. LQTS group (control state) 
-o LQTS group (epinephrine) 
Control group (control state) 
- =% - - Control group (epinephrine) 
B 
P=NS 
i i i 
100 120 140 
Heart Rate (/rain) 
Figure 4. Changes in the QT interval (A) and 
the QRS duration (B) in relation to paced 
heart rate and effect of epinephrine infusion 
(0.1 txg/kg per rain) on QT interval and QRS 
duration in 11 patients with LQTS and 10 
control patients. 
(30%), respectively, at paced heart rates of 100, 120 and 140 
beats/rain. Epinephrine-induced changes in the dispersion of 
MAPD90 in the LQTS group were not frequency dependent. 
In the control group, there were no significant changes in mean 
dispersion of MAPD90 (19 + 11, 16 _+ 10 and 18 _+ 4 ms) at 
any paced heart rate during epinephrine infusion. Hence, the 
differences in the mean dispersion of MAPD90 between the 
two groups increased to 43, 36 and 17 ms at paced heart rates 
of 100, 120, and 140 beats/rain, respectively, during epineph- 
rine infusion. Although there was also an attenuation i the 
differences of the mean dispersion of MAPD90 between the 
two groups by increasing heart rate even during epinephrine 
infusion, the dispersion of MAPD90 was significantly (p < 
0.05) much greater in the LQTS group than in the control 
group at heart rates of 100, 120 and 140 beats/rain. These 
findings indicate that increasing the heart rate by atrial pacing 
did not decrease the dispersion of MAPD90 significantly 
during epinephrine infusion (Fig. 3B). 
Response of QT interval to heart rate (Table 3). During 
the control state, at paced heart rates of 70, 80, 100, 120 and 
140 beats/rain, respectively, the mean QT interval was 490 _+ 
63,429 _+ 46, 396 _+ 49, 360 + 39 and 324 _+ 31 ms in the LQTS 
group (n = 11) (Fig. 1, upper panel) and 391 _ 31, 363 _+ 25, 
336 + 25, 321 _+ 23 and 285 _+ 22 ms in the control group 
(n = 10) (Fig. 2, upper panel) and was also significantly 
(p < 0.001) longer in the LQTS group than in the con- 
trol group at all heart rates tested, as with the MAPD90. 
Although the mean QT interval decreased with increasing 
heart rate in both groups, the differences in mean QT interval 
between the LQTS and control groups were 99, 66, 60, 39 and 
39 ms at each paced heart rate, indicating attenuation of 
differences in the QT interval between the two groups at faster 
heart rates. Moreover, the QT interval, which was examined 
over the range of paced heart rates, was significantly onger at 
slower than at faster paced heart rates in the LQTS group (p < 
0.005). 
During epinephrine infusion, the QT interval was pro- 
longed significantly (p < 0.001 by ANOVA) to 437 _+ 57, 411 _+ 
50 and 368 _ 36 ms, respectively, in the LQTS group at paced 
heart rates of 100, 120 and 140 beats/min (Fig. 1, lower panel). 
The degree of prolongation ofthe QT interval compared with 
that in the control state was 41 ms (i0%), 51 ms (14%) and 
44 ms (14%) at paced heart rates of 100, 120 and 140 
beats/rain, respectively. Epinephrine-induced changes in the 
QT interval in the LQTS group were not frequency dependent. 
In the control group, there were no significant changes in QT 
interval (335 _+ 19, 328 _+ 21 and 285 _+ 21 ms) at each paced 
heart rate (Fig. 2, lower panel). Therefore, the differences in 
the mean QT interval between the two groups increased to 
102, 83 and 83 ms at paced heart rates of 100, 120 and 140 
beats/rain, respectively, during epinephrine infusion. When the 
QT interval was examined over the range of paced heart rates, 
there was no significant frequency-dependent relation be- 
tween the two groups during epinephrine infusion, in- 
dicating that increasing heart rate by atrial pacing did not 
shorten the QT interval significantly during epinephrine infu- 
sion (Fig. 4A). 
Response of QRS duration to heart rate (Table 3). The 
QRS duration was nearly constant at all paced heart rates, and 
there was no frequency-dependent ffect in either group. 
There were no significant differences between the two groups 
at any of the paced heart rates tested. Epinephrine did not 
change the QRS duration significantly in either group (Fig. 
4B). 
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Table 3. QT Interval and QRS Duration in Relation to Paced Heart Rate and Effect of Epinephrine on QT Interval and QRS Duration i  11 
Patients With Congenital Long QT Syndrome and 10 Control Patients 
Paced Heart Rate 
70 beats/rain 80 beats/rain 100 beats/rain 120 beats/rain 140 beats/rain 
QT QRS QT ORS QT QRS QT ORS QT ORS 
No. of Sites Interval Duration Interval Duration Interval Duration Interval Duration Interval Duration 
Group Sampled (ms) (ms) (ms) (ms) (ms) (ms) (ms) (ms) (ms) (ms) 
Control state 
LQTS group 11 
Control group 10 
5 
Epinephrine 
LQTS group 11 
Control group 10 
A 
490 + 63* 79 = 8 429 ± 46* 79 + 8 396 ± 49* 80 ± 10 360 : 39* 80 + 9 324 ± 31' 78 ± 6 
391 ± 26 85 = 10 363 ± 25 84 ± 10 336 + 25 84 ± 10 321 = 23 84 ± 10 285 ± 22 84 ± 10 
99 6 66 5 611 4 39 4 39 6 
437 : 57t$ 79 ± 7 411 ± 50t{ 80-  10 368 + 36'$ 80 ± 10 
335 + 19 82 ~ 10 328 ± 21 82 ± 10 285 ± 21 82 ± 10 
102 3 83 2 83 2 
*p < 0.001 versus Control group (Control state), tp < 0.001 versus congenital long QT syndrome (LQTS) group (Control state). :[:p < 0.001 versus Control group 
(Epinephrine). Data are expressed as mean * SD or difference (A) between mean value in LQTS group and that in Control group for each heart rate. 
Discuss ion  
There were two major new findings of the present study: 1) 
Increasing heart rate by atrial pacing shortened the prolonged 
monophasic action potential duration and QT interval and 
decreased the increased ispersion of monophasic action po- 
tential duration in patients in the LQTS group in the absence 
of sympathetic (epinephrine) stimulation; and 2) epinephrine 
blunted the effects of increased heart rate by atrial pacing on 
these repolarization abnormalities. 
Response of MAPD90 and QT interval to heart rate in 
congenital LQTS. It was previously reported (8-10) that 
increasing the heart rate with exercise or isoproterenol infu- 
sion produces aparadoxic prolongation ofthe QT interval and 
may precipitate ventricular arrhythmias in patients with con- 
genital LQTS. When the heart rate was increased by exercise 
and isoproterenol infusion, sympathetic a tivity increased con- 
comitantly. It is well known that sympathetic stimulation plays 
an important role in ventricular repolarization abnormalities in 
congenital LQTS (9,14-16,18). Bhandari et al. (19) reported 
the response of the QT interval to atrial pacing in control 
subjects and patients with congenital LQTS. They demon- 
strated that atrial pacing, which has little effect on sympathetic 
activity, significantly shortened QT interval, and the degree of 
percent change in QT interval shortening was similar in the 
two groups. Our results were compatible with their finding with 
respect o shortening QT interval by atrial pacing in patients 
with congenital LQTS. In our study the degree of shortening in
repolarization variables (MAPD90, dispersion of MAPD90 
and QT interval) by increasing the heart rate was much greater 
in patients with congenital LQTS than in control patients. 
These bradycardia-dependent r polarization abnormalities 
have been recognized as characteristic of patients with ac- 
quired LQTS, and tachycardia-dependent r polarization ab- 
normalities have been suggested (20) in patients with congen- 
ital LQTS. However, Jackman et al. (20) suggested that both 
congenital and acquired LQTS have a similar membrane 
defect with diminished repolarizing currents. 
Recently, linkage studies (21,22) have demonstrated three 
separate loci for this inherited isorder (i.e., on chromosomes 
3, 7 and 11), and three forms of LQTS have been shown 
(23-25) to result from mutations in ionic channel genes on 
chromosomes 3, 7 and 11. Mutations in the chromosome 3 
gene SCN5A, a sodium ion channel gene, were linked to LQT3 
syndrome, whereas those in the chromosome 7 gene HERG, a 
rapid-activating delayed rectifier potassium ion current (IKr) 
gene (26), were related to LQT2 syndrome. Recently, muta- 
tions in the chromosome 11 gene KVLQT1, a potassium ion 
channel gene, were found to be responsible for LQT1 syn- 
drome (25). Mutations in the gene SCN5A are responsible for 
the inactivation of the sodium ion current, and mutations in 
gene HERG and KVLQT1 are likely to impair expression of 
potassium ion current. In the present study, genotypes of the 
11 patients with congenital LQTS were not investigated. Moss 
et al. (27) reported that the three genes responsible for LQTS 
were associated with a different T wave pattern on the ECG. In 
most patients within our study, congenital LQTS may be 
associated with chromosome 7 or 11 or other unknown genes 
rather than chromosome 3 on the basis of their T wave pattern 
(data not shown). If most of our patients have mutations inthe 
chromosome 7 gene HERG, action potential duration may 
shorten to a greater extent with faster than with slower pacing 
rate because of reverse-use dependency aused by depressed 
delayed rectifier potassium ion current (28). Schwartz et al. 
(29) reported that patients with congenital LQTS linked to 
chromosome 3 had a shortened QT interval in response to 
increases in heart rate. Even if LQTS in some of our patients 
is linked to chromosome 3, action potential duration may 
shorten similarly with rapid pacing. 
Response of dispersion of MAPD90 to heart rate in 
congenital LQTS. Recent experimental nd clinical studies 
using monophasic action potentials have demonstrated (14- 
16,20) that early afterdepolarizations a d prolonged action 
potential duration play an important role in ventricular ar- 
rhythmias in congenital LQTS. However, it is hypothesized 
1276 HIRAO ET AL. JACC Vol. 28, No. 5 
FREQUENCY DEPENDENCY IN CONGENITAL LQTS November 1, 1996:1269-77 
that an electrophysiologic substrate of ventricular arrhythmias 
may be created by an increased ispersion of repolarization 
(30-32). Kuo et al. (31) assumed that when the increase in 
dispersion of repolarization reached a critical level, propaga- 
tion of premature impulses originating from the area with a 
short action potential duration encountered a block in the area 
with a long action potential duration and created conditions 
favorable for reentry. This concept has been further investi- 
gated by several clinical methods. Linker et al. (33) and Priori 
et al. (34) demonstrated the presence of an increased QT 
interval dispersion in patients with congenital LOTS using the 
surface 12-lead ECG. Shimizu et al, (35) also reported an 
increased QT interval dispersion and recovery time by record- 
ing 87-lead body surface mapping. In the present study using 
monophasic action potential, the dispersion of MAPD90 was 
greater in the LOTS group than in the control group at all 
paced heart rates and decreased with increasing heart rate in 
patients with congenital LQTS. These findings support the 
efficacy of permanent pacemaker therapy in congenital LOTS 
because increasing the heart rate without sympathetic a tivity 
may improve the electrophysiologic substrate of ventricular 
arrhythmias. 
Effect of epinephrine on relation between ventricnlar epo- 
larization and heart rate. We previously reported (14-16) 
that isoproterenol repinephrine prolonged the MAPD90 and 
the QT interval, increased the dispersion of MAPD90 and 
induced early afterdepolarization n patients with congenital 
LQTS. The present study further evaluated the effect of 
epinephrine on the relation between ventricular repolarization 
and heart rate. Epinephrine significantly prolonged the 
MAPD90 and the QT interval and increased the dispersion of 
MAPD90 at paced heart rates of 100, 120 and 140 beats/min i
patients with congenital LQTS. The degree of prolongation of 
MAPD90 and the QT interval by epinephrine compared with 
the control state was relatively constant, and rate-dependent 
changes in these repolarization variables were attenuated by 
epinephrine. These results indicate that permanent pacemaker 
therapy may not be sufficient o prevent ventricular arrhyth- 
mias during sympathetic stimulation i  congenital LQTS. 
Study limitations. There are several imitations to the 
present study. Monophasic action potential recordings were 
obtained from only two or three endocardial sites in each 
patient. Especially for the left ventricle, monophasic action 
potential recordings were obtained in all patients with congen- 
ital LQTS but in only six control patients. This nonuniformity 
of recording sites limits the calculations of dispersion of 
monophasic action potential durations across both ventricles. 
More detailed mapping of monophasic action potential record- 
ings is necessary to define dispersion more precisely. Further- 
more, we could only evaluate the rate-dependent effects of 
epinephrine on repolarization variables for narrow range of 
heart rates (100, 120 and 140 beats/rain). It remains for other 
studies to examine a wider range of heart rates to evaluate 
more completely the rate-dependent ffects of epinephrine on 
repolarization variables. 
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